Share Twitter LinkedIn Facebook Email Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on integration of new agents for advanced HCC treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read